在高血压大鼠中,金纳普利治疗抑制了全球纵向应变和机械功能的下降
Alexander J Wilson1, Gregory B Sands2, Vicky Y Wang1
1Department of Radiology, Stanford University, Stanford, California, USA.
Journal of hypertension
|July 19, 2023
概括
ангиотензин转化酶 (ACE) 抑制剂治疗改善了高血压大鼠的心脏功能. 在这项研究中,这种治疗保留了心脏机械功能障碍的早期生物标志物全球纵向菌株 (GLS).
科学领域:
- 心脏病学 心脏病学
- 生物标志物 生物标志物
- 医疗成像医学成像
背景情况:
- 左心室 (LV) 全球纵向应变 (GLS) 被认为是心脏机械功能障碍的早期指标.
- 高血压心脏病可能导致心脏功能受损.
研究的目的:
- 在高血压心脏病模型中,评估血管酶转化酶 (ACE) 抑制剂治疗对LV GLS和机械功能的影响.
- 为了确定ACE抑制剂是否可以减轻与高血压相关的心脏功能障碍.
主要方法:
- 使用自发高血压大鼠 (SHRs) 作为高血压心脏病的模型,使用Wistar京都大鼠 (WKY) 作为对照.
- 从3个月大开始,向SHRs (TSHRs) 的一个子集注射奇纳普里尔 (一种ACE抑制剂).
- 使用4.7T临床前扫描仪进行标记的心脏磁共振成像 (MRI),以评估LV功能和GLS.
主要成果:
- 与WKY相比,SHR在多个时间点 (3,14,24个月) 呈现出明显较低的LV射出分数 (EF).
- 在24个月后,用ACE抑制剂治疗的TSHRs与未经治疗的SHRs相比显著改善了LV EF.
- 在14个月和24个月的WKY相比,SHR的峰值GLS大小显著降低,在24个月的未经治疗的SHR相比,TSHR显著降低.
结论:
- 在高血压大鼠中,ACE抑制剂治疗有效地减轻了全球纵向应变的下降.
- 该研究表明,与未经治疗的对照组相比,ACE抑制剂治疗显著提高了高血压大鼠的LV EF和GLS大小.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
693
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
693
Antihypertensive Drugs: Angiotensin II Receptor Blockers
784
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
784
Hypertension II: Pathophysiology
16
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
16
Antihypertensive Drugs: Direct Renin Inhibitors
695
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
695
Antihypertensive Drugs: Vasodilators
570
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
570


